Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Vincent Salomon, Anne ^a,b   Benhamo, Vanessa ^a,b   Gravier, Eléonore ^a,c   Rigaill, Guillem ^a,d   Gruel, Nadège ^a,b   Robin, Stéphane ^d   de Rycke, Yann ^a   Mariani, Odette ^a   Pierron, Gaëlle ^a   Gentien, David ^a   Reyal, Fabien ^a   Cottu, Paul ^a   Fourquet, Alain ^a   Rouzier, Roman ^a   Sastre Garau, Xavier ^a   Delattre, Olivier ^b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d AgroParisTech   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER PROGNOSIS; CHROMOSOME BREAKAGE; DIAGNOSTIC TEST ACCURACY STUDY; EARLY STAGE LUMINAL BREAST CARCINOMA; GENOMIC GRADE INDEX; GENOMIC INSTABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS; UNIVARIATE ANALYSIS; VALIDATION STUDY;

ADULT; AGED; BREAST NEOPLASMS; CELL PROLIFERATION; CHROMOSOME BREAKPOINTS; COMPUTATIONAL BIOLOGY; DISEASE-FREE SURVIVAL; FEMALE; GENOMIC INSTABILITY; GENOTYPING TECHNIQUES; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS;

EID: 84885437395     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076496     Document Type: Article

References (43)

1. Bedard PL, Cardoso F, (2011) Can some patients avoid adjuvant chemotherapy for early-stage breast cancer? Nat Rev Clin Oncol 8: 272-279. doi:10.1038/nrclinonc.2011.19. PubMed: 21364525.
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874. doi:10.1073/pnas.191367098. PubMed: 11553815.
3. Foulkes WD, Reis-Filho JS, Narod SA, (2010) Tumor size and survival in breast cancer--a reappraisal. Nat Rev Clin Oncol 7: 348-353. doi:10.1038/nrclinonc.2010.39. PubMed: 20309006.
4. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, et al. (2005) Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clin Cancer Res 11: 5678-5685. doi:10.1158/1078-0432.CCR-04-2421. PubMed: 16115903.
5. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, et al. (2012) Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486: 405-409. doi:10.1038/nature11154. PubMed: 22722202.
6. Network TCGA (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
7. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, et al. (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400-404. PubMed: 22722201.
8. Chin SF, Wang Y, Thorne NP, Teschendorff AE, Pinder SE, et al. (2007) Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene 26: 1959-1970. doi:10.1038/sj.onc.1209985. PubMed: 17001317.
9. Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, et al. (2011) A refined molecular taxonomy of breast cancer. Oncogene 31: 1196-1206. PubMed: 21785460.
10. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, et al. (1992) Pathological prognostic factors in breast cancer. II- Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20: 479-489. PubMed: 1607149.
11. Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, et al. (2011) Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 132: 895-915. PubMed: 22048814.
12. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272. doi:10.1093/jnci/djj052. PubMed: 16478745.
13. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, et al. (2011) Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 29: 4273-4278. doi:10.1200/JCO.2010.31.2835. PubMed: 21990413.
14. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, et al. (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10: 529-541. doi:10.1016/j.ccr.2006.10.009. PubMed: 17157792.
15. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352. PubMed: 22522925.
16. Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, et al. (2011) Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 71: 3447-3452. doi:10.1158/0008-5472.CAN-10-3667. PubMed: 21270108.
17. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z, (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38: 1043-1048. doi:10.1038/ng1861. PubMed: 16921376.
18. Chibon F, Lagarde P, Salas S, Pérot G, Brouste V, et al. (2010) Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 16: 781-787. doi:10.1038/nm.2174. PubMed: 20581836.
19. Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bündgen NK, et al. (2009) The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer 124: 1552-1564. doi:10.1002/ijc.24017. PubMed: 19101988.
20. Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, et al. (2011) Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev 20: 2183-2194. doi:10.1158/1055-9965.EPI-11-0343. PubMed: 21784954.
21. Gravier E, Pierron G, Vincent-Salomon A, Gruel N, Raynal V, et al. (2010) A prognostic DNA signature for T1T2 node-negative breast cancer patients. Genes Chromosomes Cancer 49: 1125-1134. doi:10.1002/gcc.20820. PubMed: 20842727.
22. Russnes HG, Vollan HK, Lingjaerde OC, Krasnitz A, Lundin P, et al. (2010) Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2: 38ra47. PubMed: 20592421.
23. Smid M, Hoes M, Sieuwerts AM, Sleijfer S, Zhang Y, et al. (2010) Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res Treat 128: 23-30. PubMed: 20632083.
24. Blamey RW, Hornmark-Stenstam B, Ball G, Blichert-Toft M, Cataliotti L, et al. (2009) ONCOPOOL- a European database for 16,944 cases of breast cancer. Eur J Cancer 46: 56-71.
25. Elston CW, Ellis IO, (1991) Pathological Prognostic Factors in Breast cancer. The value of histological Grade in Breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410. doi:10.1111/j.1365-2559.1991.tb00229.x. PubMed: 1757079.
26. Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, et al. (2008) Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 14: 1956-1965. doi:10.1158/1078-0432.CCR-07-1465. PubMed: 18381933.
27. Reyal F, Bollet MA, Caly M, Gentien D, Carpentier S, et al. (2012) Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma. PLOS ONE 7: e35184. doi:10.1371/journal.pone.0035184. PubMed: 22529987.
28. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, et al. (2011) Assessment of KI67 in breast cancer: recommendations from the International KI67 in Breast Cancer working group. J Natl Cancer Inst 103: 1656-1664. doi:10.1093/jnci/djr393. PubMed: 21960707.
29. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, et al. (2011) Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747. doi:10.1093/annonc/mdr304. PubMed: 21709140.
30. Prat A, Cheang MC, Martín M, Parker JS, Carrasco E, et al. (2013) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31: 203-209. doi:10.1200/JCO.2012.43.8150. PubMed: 23233704.
31. Vincent-Salomon A, Raynal V, Lucchesi C, Gruel N, Delattre O, (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40: 802; author reply:-802. doi:10.1038/ng0708-810. PubMed: 18583967.
32. Rigaill G, (2010). runed dynamic programming for optimal multiple change-point detection. arXiv:10040887v1.
33. Zhang NR, Siegmund DO, (2007) A modified Bayes information criterion with applications to the analysis of comparative genomic hybridization data. Biometrics 63: 22-32. doi:10.1111/j.1541-0420.2006.00662.x. PubMed: 17447926.
34. Picard F, Lebarbier E, Hoebeke M, Rigaill G, Thiam B, et al. (2011) Joint segmentation, calling, and normalization of multiple CGH profiles. Biostatistics 12: 413-428. doi:10.1093/biostatistics/kxq076. PubMed: 21209153.
35. Piccart-Gebhart MJ, Sotiriou C, (2007) Adjuvant chemotherapy--yes or no? Prognostic markers in early breast cancer. Ann Oncol 18 (Suppl 12):: xii2-xii7. doi:10.1093/annonc/mdm532. PubMed: 18083699.
36. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P, (2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17: 323-334. doi:10.1016/j.breast.2008.02.002. PubMed: 18455396.
37. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. N Engl J Med 351: 2817-2826. doi:10.1056/NEJMoa041588. PubMed: 15591335.
38. Ignatiadis M, Sotiriou C, (2011) Breast cancer: Should we assess HER2 status by Oncotype DX? Nat Rev Clin Oncol 9: 12-14. doi:10.1038/nrclinonc.2011.188. PubMed: 22143144.
39. Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, et al. (2011) High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol 29: 4279-4285. doi:10.1200/JCO.2011.34.7963. PubMed: 21990395.
40. Barton S, Zabaglo L, A'Hern R, Turner N, Ferguson T, et al. (2012) Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. Br J Cancer 106: 1760-1765. doi:10.1038/bjc.2012.166. PubMed: 22531639.
41. Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, et al. (2011) Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 29: 4365-4372. doi:10.1200/JCO.2011.35.3714. PubMed: 22010013.
42. Arnedos M, Scott V, Job B, De La Cruz J, Commo F, et al. (2012) Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. Eur J Cancer 48: 2293-2299. doi:10.1016/j.ejca.2012.06.014. PubMed: 22840369.
43. Krijgsman O, Israeli D, Haan JC, van Essen HF, Smeets SJ, et al. (2011) CGH arrays compared for DNA isolated from formalin-fixed, paraffin-embedded material. Genes Chromosomes Cancer 51: 344-352. PubMed: 22162309.